Initial Evaluation of Anti-1-Amino-F-18 Flurocyclobutane-1carboxylic acid (anti-3[18F] FACBC) in the Assessment of Head and Neck Cancer: A pilot Study.

Head and neck cancer (HNC) accounts for 3% of malignancies in the United States, with 50,000 new cases expected in 2012. Traditional assessment has relied on anatomic imaging such as ultrasound, CT, and MRI. Fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) was approved by Center for Medicare and Medicaid Services (CMS) for the diagnosis, staging, and restaging of HNC in July 2001. PET/CT was subsequently approved in April 2009. Addition of metabolic imaging significantly improved the accuracy of HNC assessment, especially in the detection of cervical nodal and distant metastasis. In an effort to overcome the limitations of PET and FDG, tracers have been developed which rely on amino acid transport such as anti-1-Amino-F-18 Flurocyclobutane-1carboxylic acid (anti-[18F] FACBC).

The purpose of this pilot study is to determine the degree to which anti-18F-FACBC uptake is present in HNC and to establish an ideal imaging protocol. Our long-term goal is to determine if PET imaging with anti-18F-FACBC can lead to better patient care through improved characterization.


Funding Agency: Internal
PI: Tuba Kendi, MD

For further information about this study